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Altering Oligomerization of EphA2 via Mutations in the Intracellular Domain
Abstract:
Eph receptor tyrosine kinases (RTKs) are activated by membrane-bound ligands called
ephrins. Eph RTKs are divided into two subclasses, each activated by a specific classes of the
ligand ephrin. The overexpression of Eph receptors is correlated to cancer cell metastasis in several
different types of cancers. Studies with the EphA2 extracellular domain (ECD) and ephrinA1
ligand have shown that upon binding of ephrin to the receptor, EphA2 undergoes increased
oligomerization and activation. This indicates that oligomerization is intimately connected to
kinase activity. High resolution crystal structures of the EphA2 ECD have revealed some details
of these ligand bound oligomers, as well as ligand free clusters. Despite these structures, there is
still no comprehensive understanding of the role that each domain plays in ligand-dependent and
ligand-free EphA2 oligomerization and activation. Here we report our investigation of the role that
the intracellular domain (ICD) plays on EphA2 oligomerization. We first deleted the sterile alpha
motif (SAM) domain from the C-terminus of the protein and measured oligomerization with a
time-resolved, fluorescence spectroscopy method with single molecule sensitivity, called
fluorescence correlation spectroscopy (FCS). Deleting the SAM domain from the intracellular
domain displayed reduced mobility of EphA2, and an increased brightness. From this we
concluded that the SAM domain has a role in inhibiting oligomerization of the un-liganded, full-

length receptor. In future research, our aim is to investigate the role that other motifs play in
receptor oligomerization. This work will have clinical applications, especially in cancers where
EphA2 is mutated or overexpressed.
Introduction:
Eph receptor tyrosine kinases are the largest known subfamily of receptor tyrosine kinases.1
Eph RTKs are divided into two subclasses, EphA and EphB. Their ligands, ephrin are also divided
into respective A and B classes. In addition, there are nine different
EphA RTKs, which bind to six A-ephrin ligands, and six different
EphB RTKs (as well as EphA4), which bind to three B-ephrin
ligands.1 These Eph RTKs play a role in many aspects of cells, from
morphology, to communication.1 What is noteworthy for this project
is that RTKs conduct biochemical signals across the plasma
membrane through dimerization.1 Eph RTK activation can be
characterized by ligand binding, oligomerization followed by the
phosphorylation of tyrosine residues in the juxtamembrane segment
Figure 1. Eph receptor tyrosine kinases.
Diagram showing different domains.

(JMS), and kinase domains of the protein.2 Key mutations to

different domains of Eph RTKs often cause alterations in the dimerization and signaling functions
of the RTKs.3 Post-activation of these RTKs the protein is internalized and degraded.4,5 In
addition, Eph RTKs are often thought to be related to cancer metastasis.3 It has been shown that
in some types of cancers certain Eph RTKs are overexpressed, and many Eph RTK somatic
mutations are oncogenic mutations.3
Mutations to Eph RTKs have different effects on the oligomerization, and therefore affect
cell signaling depending on the domain the mutation is located in. Eph RTKs have many domains

including: a ligand binding domain, cysteine-rich domain, two consecutive fibronectin III
domains, a transmembrane domain, juxtamembrane domain, kinase domain, SAM domain, and a
PDZ binding motif.1 (Fig. 1) Our lab is highly interested in introducing key mutations, via sitedirected mutation and genetic recombination, into each of the domains of Eph RTKs and observing
the functional outcome on the dimerization of the receptors. Our lab elucidates changes in
dimerization, and cell signaling, and how those changes influence cancer cells.
Results:
In order to investigate the functions of each of the domains, two serial truncations were
performed on the protein. The fluorescent tag was maintained at the end of the protein despite the
deletions. First a truncation was done to remove the SAM
domain and everything following it, denoted as ΔSAM. A
second mutation was performed to remove the Kinase domain
and everything following it, denoted as ΔKS. These mutations
were performed via site-directed mutagenesis, and the
plasmid was expressed in a mammalian cell line termed
DU145, a human prostate cancer cell line.5 DU145 cells were
selected for the experiment because they express very low
levels of endogenous EphA2.
Figure 2. Truncation schematic of EphA2 RTK

Post-transfection,

these

cells

were

used

in

immunoblot assays with and without the ligand EA1-fc using a primary antibody (pY-EphA/B)
that is against the phospho-dityrosine motif found in the juxtamembrane domain of most Eph
receptors. (Fig. 3) Looking at the short exposure time in the unliganed section of the figure the

wild type and the full length receptors,
denoted

A2WT

and

A2-GFP

respectively, there appears to be no
phosphorylation taking place.

When

observing the ΔSAM construct (A2ΔSGFP) the short incubation with the
antibody

shows

increased

phosphorylation. This shows that the
receptor may be active with this
Figure 3. Western blot of EphA2 constructs without ligand. Figure from
Shi et. al.5

truncation despite the fact that there is

no ligand bound. The vector is a part of the
immunoblot to show a control value for no
phosphorylation. When the antibodies were
applied on the ΔSAM construct given the
ligand EA1-Fc phosphorylation was notably
higher than either the ΔSAM construct without
ligand or the full length receptor. (Fig. 4) This
supports the hypothesis that the kinase domain
Figure 4. Western blot of EphA2 constructs with ligand EA1-Fc.
Figure from Shi et. al.5

undergoes activation upon the deletion of the
SAM domain.

Any small amounts of

phosphorylation shown under the wild type, and full length receptors after long exposure to the
antibody can be explained by endogenous protein. DU145 is an excellent candidate for this
experiment specifically because it has very low levels of endogenous EphA2.

Morphological changes can also be observed with the truncation mutations (Fig. 5).
Examining the morphology of the
DU145 cells it can be seen that when
ligand is added to the full length
receptor (EphA2-GFP) the cells
cluster. When no ligand is bound to
the full length receptor the image
resembles that of the control for no
clustering (Vec/Ctl). However, the
ΔSAM construct (EphA2-ΔS-GFP)
shows substantial clustering without
the ligand present. This clustering is
Figure 5. Image showing morphological, and clustering differences of DU145
cells with different constructs. Figure from Shi et. al.5

similar to what is shown in the image
of the full length receptor with added

EA1-Fc ligand. In addition, human growth factor (HGF) normally induces cell scattering, and
somewhat deters clustering. It is shown that the full unliganded receptor has no clustering in the
presence of HGF. When ligand is added to the receptor, clustering occurs despite the HGF, but
not quite the amount of clustering seen with the liganded receptor without HGF. When the ΔSAM
construct is observed with HGF, it is shown that clustering occurs similar to that of the full length
receptor with HGF. This supports the phosphorylation data shown in the previous figure. The
receptor seems to undergo activation when missing the ΔSAM domain without ligand being added.

To investigate this idea further, fluorescence correlation spectroscopy (FCS) was used.
FCS is able to reveal the molecular brightness of the fluorescent protein, the mobility, as well as
the density of the receptor in the membrane.5 Molecular brightness is a measure of the photons
emitted from a receptor or a
complex of receptors per unit
of

time.

The

molecular

brightness

is

directly

proportional to the amount of
receptors in a given complex.6
As an example, having a
Figure 6. Molecular brightness of EphA2 constructs. Figure from Shi et. al.5

dimer with a fluorescent tag

would show twice the molecular brightness of a monomer.5 The average molecular brightness of
the full length receptor is 466 cpsm, and the average molecular brightness of the ΔSAM construct
is 633 cpsm. (Fig. 6) This shows that the molecular brightness of the ΔSAM construct without
ligand, is significantly higher than the molecular brightness of the full length receptor without
ligand. Src-GFP and Myr-GCN4-GFP are monomer and dimer control values respectively. Src
is a known monomer, and the GCN4 portion of Myr-GCN4 forces a dimer conformation.5 The
molecular brightness of the ΔSAM construct is not significantly different from the dimer control,
however, is significantly different from the monomer control. Again it is indicated that the deletion
of the SAM domain allows oligomers, and activation of the receptor.7 The ΔKinase construct
(EphA2ΔKS-GFP) showed an even higher molecular brightness than the ΔSAM construct. In fact,
the ΔKinase construct seems to be elevated just above the dimer control value. The difference in
molecular brightness between the ΔKinase construct and the ΔSAM construct can likely be

accredited to differing equilibrium distribution of oligomer states.5 Overall it can be concluded
based on molecular brightness that the truncated receptors seem to have higher oligomer states.
The diffusion coefficients tell a similar story. The diffusion coefficient is a measure of
mobility of the receptor within
the membrane. The full length
receptor
coefficient

has

a

value

diffusion
of

0.30

(μm2/s). This is about twice the
value of the ΔSAM construct
and the ΔKinase construct.
Figure 7. Diffusion coefficients for the different EphA2 constructs. Figure from Shi
et. al.5

Mobility in the membrane is

measured via the diffusion coefficient utilizing fluorescence recovery after photo-bleaching
(FRAP). It is concluded that the larger the membrane bound protein is, the slower the rate of
diffusion.8,9 From the diffusion coefficients of the different constructs, it can be concluded, that
the mobility of the truncated constructs is greatly reduced due to larger cluster formation. This
confirms the previously mentioned idea that deletion of the SAM domain causes activation of the
receptor regardless of ligand presence. This also shows that the kinase domain is in no way
inhibiting activation of the receptor.
Overall, from the results it can be concluded that the SAM domain of EphA2 plays a major
role in the inhibition of receptor activation, and signaling.

Methods:
This project used plasmids that contain human EphA2, and were labeled with eGFP
fluorescent proteins at the C-terminus. The starting plasmids with not truncation mutates were
created by our collaborators at Case Western Reserve University. The nucleic acid sequences of
these plasmids are known, and have been dissected and annotated using a free program called
Genome Compiler. Genome Compiler along with an online tool made by New England Biolabs
(NEB) were used to design the truncation mutations performed. E. coli strains used consisted of
DH5α, NEB5α, and NEB10β.
Site-directed mutagenesis was conducted using reagents purchased from NEB. Primers
were designed for mutation as previously described. There are three options for mutation using
site-directed

mutagenesis

which

are

substitution, deletion, and insertion. (Fig. 8)
Figure 8. Site-directed mutagenesis schematic.

The goal here is to have primers with a high

enough annealing affinity that they bind to the template DNA, but not so high that they are not
able to be easily denatured for replication in Polymerase Chain Reaction (PCR).
Western blotting was used to measure the phosphorylation of tyrosine within the receptor.
Western blotting is an experiment that allows a specific protein to be located. The antibody pYEphA/B was introduced to bind to our protein, and a secondary antibody was introduced as a
reporter of the magnitude of primary antibody binding.10 Another method of data collection
involved a custom built fluorescence microscope. In order to detect changes in dimerization,
fluorescence cross-correlation spectroscopy (FCCS) was used. (Fig. 9)

FCCS can monitor

molecular interactions, enzymatic reactions, and dynamic colocaliztion.11 With use of two
different colored lasers, and two corresponding photon detectors, the emission of the two

fluorescent proteins can be detected. In this project these fluorophores would be eGFP as
mentioned previously, and mCherry. This method allows the cross-correlation of the diffusion of
proteins to be observed.

Figure 9. FCCS schematic with sample curves. Figure from Shi et. al.5

Another method to detect oligomerization is fluorescence resonance energy transfer
(FRET). FRET is similar to FCCS, except FRET is used to indicate distance on a molecular level.12
Rather than measured correlated diffusion of fluorophores, FRET measures the energy transferred
from a fluorophore in an excited electronic state to a chromophore.12 The amount of energy
transferred between the fluorophores has a direct relation to distance.12 Note that when any
spectroscopy data is taken for membrane bound receptors, the laser is always focused on the
lamellipodial region of the cell.5 (Fig. 9) This is to ensure that what is being detected is the result
of membrane function only. Luckily any data taken in which an organelle or anything nonmembrane appeared under the laser is noticeable and thrown out as outliers. Similar outliers

appear when data is taken too close to the edge of the cell. All FCS for this project is done in vivo,
and the cells often move out of the area that the laser is focused on.
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